Try, Try, Try Again

Bucindolol, a beta-blocker that never made it to the market because a patient study showed it did not reduce the risk of death due to high blood pressure and heart failure, may be making a comeback. According to the Wall Street Journal, researchers report that heart failure patients with a specific genetic mutation given the drug were 48 percent less likely to die of heart-related problems and 44 percent less likely to be hospitalized, as compared to those given placebo.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.